Stock Analiz

EyePoint, Inc. EYPT

Biotechnology: Laboratory Analytical Instruments · data as of November 13, 2026

$0.31Market cap $35M
Open the interactive analysis →

EyePoint, Inc. (EYPT) is a industrial company listed in the US with a market value of about $35M. In the twelve months to September 30, 2026 it had revenue of $3M and net income of -$343M, a net margin of -13281.2%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -2% a year, a 5-year average ROIC of -41%.

About EyePoint

EyePoint is listed in the US and classified in biotechnology: laboratory analytical instruments. Revenue went from $27M in 2015 to $31M in 2025, growth of about 1.7% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 96% over three years (dilution for shareholders). It spends 705% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S13.5
P/B0.3
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-859.2%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-27.5%
Revenue growth (5 yrs, per year)-1.8%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-320.2%
ROIC (5-yr avg.)-41.4%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$3M$31M$43M$46M$41M$37M$34M$20M$5M$8M$2M
Net income-$343M-$232M-$131M-$71M-$102M-$58M-$45M-$57M-$86M-$18M-$22M
Free cash flow-$299M-$243M-$130M-$2M-$67M-$50M-$15M-$57M—-$21M-$16M
EPS (diluted)$-3.97$-3.17$-2.32$-1.82$-2740.00$-2030.00$-3540.00$-5440.00$-12699.63$-5199.85$-6799.80
Net margin-13281.2%-739.4%-302.4%-153.8%-247.0%-158.1%-131.8%-278.9%-1884.2%-245.2%-1330.1%
ROIC—-58.5%-32.0%-21.8%-69.8%-24.7%-62.8%-81.2%-55.8%-139.3%-103.5%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 8 analysts is $8.31, 2617% above the current price; targets range from $0.50 to $31.00; the consensus rating is “Hold”; expected EPS is $-3.73 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does EyePoint pay a dividend?

Not currently.

Is EyePoint a good stock to buy?

We do not give buy or sell advice. EyePoint scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.